VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.
Climate change is making us sick — and the healthcare system is exacerbating the problem. But new strategies suggest it’s possible to clean up our act.
Looking to make a name for yourself in the digital art world? Then you’re in luck – building an online art store and marketing your products has never been ...
From business leaders and industry experts, here are five trends that have the potential to create that watershed moment for sustainability and social impact in 2025. This moment calls for ...